calcium gluconate
Approved
Jun 15, 2017
Calcium gluconate is the calcium salt of gluconic acid and is used as a mineral supplement and medication. As a medication it is used by injection into a vein to treat low blood calcium, high blood potassium, and magnesium toxicity. Supplementation is generally only required when there is not enough calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets. It can also be taken by mouth but is not recommended for injection into a muscle. — Wikipedia
Clinical trial activity
11 trials · 13 clinical orgs · 8 marketing orgs
Earliest trial started Oct 1, 2014 (NCT03473613)
Timeline
2010s
2020s
- Oct 14, 2022
Nivagen Pharmaceuticals Inc. — Marketing Organization
- Aug 21, 2023
B. Braun — Marketing Organization
- Sep 5, 2023
Amneal Pharmaceuticals — Marketing Organization
- Oct 19, 2023
Somerset Pharmaceuticals — Marketing Organization
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
- Dec 30, 2025
Sagent Pharmaceuticals, Inc. — Marketing Organization
- May 4, 2026
Caplin Point Laboratories — Marketing Organization
Indications
Approved for
Studied for
- Blood Loss, Surgical · Phase 2
- Esophageal Neoplasms · Phase 1
- Hemorrhage · Phase 3
- Hypocalcemia · Phase 4
- Ovarian Diseases · Phase 3
- Parturition · Early Phase 1
- Postoperative Hemorrhage · Phase 2
- Postpartum Hemorrhage · Early Phase 1
- Pregnancy Complications · Early Phase 1
- Shock, Hemorrhagic · Phase 3
- Stroke · Phase 1
- Uterine Inertia · Phase 2
- Wounds and Injuries · Phase 3
Mechanism of action
- CalciumSupplementation
Calcium supplementation
Approval history
- approvedJun 15, 2017
Chemistry & pharmacology
SMILES
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]- Mol. weight
- 430.37 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaCalcium gluconate ↗
- ChEMBLCHEMBL2106119 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07217899 | Phase 2 | Oct 20, 2025 | University of Michigan |
| NCT06820645 | Phase 2/Phase 3 (Phase 3) | May 1, 2025 | London Health Sciences Centre, University of Western Ontario |
| NCT05958342 | Phase 2 | Mar 31, 2024 | Department of Defense, University of Pittsburgh |
| NCT05953376 | Phase 3 | Jan 31, 2024 | University of California, Irvine |
| NCT06235749 | N/A | Nov 14, 2023 | Technion University |
| NCT05973747 | Early Phase 1 (Phase 1) | Sep 1, 2023 | Stanford University |
| NCT06333691 | N/A | Oct 1, 2022 | Minia University |
| NCT04958044 | Phase 1 | Jul 12, 2021 | University of Copenhagen |
| NCT04491357 | Phase 4 | Jun 1, 2020 | University of Malaya |
| NCT03543917 | Phase 1 | Aug 8, 2017 | Fundatia Bio-Forum |
| NCT03473613 | Phase 3 | Oct 1, 2014 | Benha University |
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Benha University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Department of Defense | Government | 1 | 0 | 1 | 2024 |
| Fundatia Bio-Forum | For profit | 1 | 1 | 1 | 2017 |
| London Health Sciences Centre | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Minia University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Technion University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of California, Irvine | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Malaya | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Michigan | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Western Ontario | Academic/Hospital | 1 | 0 | 1 | 2025 |
Marketing (11)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amneal Pharmaceuticals | For profit | SYN | Sep 5, 2023 |
| Amneal Pharmaceuticals | For profit | MKTG | Sep 5, 2023 |
| B. Braun | For profit | MKTG | Aug 21, 2023 |
| B. Braun | For profit | SYN | Aug 21, 2023 |
| Caplin Point Laboratories | For profit | MKTG | May 4, 2026 |
| Fresenius | For profit | MKTG | Jun 15, 2017 |
| Fresenius | For profit | NDA | Jun 15, 2017 |
| Hq Speciality Pharma | For profit | MKTG | Oct 29, 2018 |
| Nivagen Pharmaceuticals Inc. | For profit | MKTG | Oct 14, 2022 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Dec 30, 2025 |
| Somerset Pharmaceuticals | For profit | MKTG | Oct 19, 2023 |